1- Rømer Thomsen K, Whybrow PC, Kringelbach ML. Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain. Frontiers in behavioral neuroscience. 2015; 9: 49.
2- Isella V, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I, et al. Physical anhedonia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003; 74(9): 1308-11.
3- Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology. 1998; 18(3): 135-74.
4- Starkstein SE, Jorge R, Mizrahi R, Robinson RG. The construct of minor and major depression in Alzheimer's disease. Am J Psychiatry. 2005; 162(11): 2086-93.
5- Davis C, Woodside DB. Sensitivity to the rewarding effects of food and exercise in the eating disorders. Compr Psychiatry. 2002; 43(3): 189-94.
6- McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012; 51(4): 404-11.
7- Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ, 3rd, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999; 60(4): 221-5.
8- Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009; 30(11): 563-9.
9- Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008; 455(7215): 894-902.
10- Feier G, Valvassori SS, Rezin GT, Burigo M, Streck EL, Kapczinski F, et al. Creatine kinase levels in patients with bipolar disorder: depressive, manic, and euthymic phases. Rev Bras Psiquiatr. 2011; 33(2): 171-5.
11- Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr. 2011; 33(4): 374-8.
12- Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. 2009; 61(2): 105-23.
13- Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(7): 1558-68.
14- Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr (1970). 1982; 232(4): 299-304.
15- Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR, Jr., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(6): 1155-8.
16- Garcia LS, Comim CM, Valvassori SS, Reus GZ, Andreazza AC, Stertz L, et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol. 2008; 103(6): 502-6.
17- Quan MN, Zhang N, Wang YY, Zhang T, Yang Z. Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience. 2011; 182: 88-97.
18- Reus GZ, Stringari RB, Kirsch TR, Fries GR, Kapczinski F, Roesler R, et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull. 2010; 81(6): 585-9.
19- Roman A, Rogoz Z, Kubera M, Nawrat D, Nalepa I. Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test. Pharmacol Rep. 2009; 61(6): 1069-77.
20- Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012; 32(4): 487-91.
21- John CS, Smith KL, Van't Veer A, Gompf HS, Carlezon WA, Jr., Cohen BM, et al. Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology. 2012; 37(11): 2467-75.
22- Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T, et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry. 2016; 21(10): 1351-7.
23- Reus GZ, Abelaira HM, Stringari RB, Fries GR, Kapczinski F, Quevedo J. Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Metab Brain Dis. 2012; 27(2): 175-82.
24- Mayberg HS. Modulating limbic-cortical circuits in depression: targets of antidepressant treatments. Semin Clin Neuropsychiatry. 2002; 7(4): 255-68.
25- Pradhan S KA, MacQueen G, MacMaster F. The effect of repetitive transcranial magnetic stimulation on dorsolateral prefrontal glutamate in youth with treatment-resistant depression. European Psychiatry. 2015; 29:1.
26- Young CB, Chen T, Nusslock R, Keller J, Schatzberg AF, Menon V. Anhedonia and general distress show dissociable ventromedial prefrontal cortex connectivity in major depressive disorder. Transl Psychiatry. 2016; 6: e810.
27- Michael N, Gosling M, Reutemann M, Kersting A, Heindel W, Arolt V, et al. Metabolic changes after repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal cortex: a sham-controlled proton magnetic resonance spectroscopy (1H MRS) study of healthy brain. Eur J Neurosci. 2003; 17(11): 2462-8.
28- Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry. 2014; 76(7): 517-26.
29- Chen AC, Oathes DJ, Chang C, Bradley T, Zhou ZW, Williams LM, et al. Causal interactions between fronto-parietal central executive and default-mode networks in humans. Proc Natl Acad Sci U S A. 2013; 110(49): 19944-9.
30- Zijlstra F, Veltman DJ, Booij J, van den Brink W, Franken IH. Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug Alcohol Depend. 2009; 99(1-3): 183-92.
31- Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci. 2008; 10(3): 291-9.
32- Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005; 45(5): 651-60.
33- Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995; 167(1): 99-103.
34- Kaviani H,Moosavi A, Mohit A. interview and psychological testing Tehran: Sana. 2001.
35- Kaviani H,KamiarK, Mirsepasi G. emotional reactivity in depressed patients with anhedonia. Advances in cognitive science. 2000; 2(3,4): 1-7.
36- Ahmadi Foroshani H YF, Arizi H. The effectiveness of psychodrama with spiritual content on happiness, hedonic and mental health on students Journal of Applied Psychology 2013; 7(26): 7-23.
37- Gharaii b, Mehryar a, Mehrabi f. Attribution Style in Patients with Anxiety and Depression Comorbidity. Iranian Journal of Psychiatry and Clinical Psychology. 2000; 5(4): 37-43.
38- Kazemi R, Rostami R, Khomami S, Baghdadi G, Rezaei M, Hata M, et al. Bilateral transcranial magnetic stimulation on DLPFC changes resting state networks and cognitive function in patients with bipolar depression. Frontiers in Human Neuroscience. 2018; 12.
39- Kazemi R, Rostami R, Khomami S, Horacek J, Brunovsky M, Novak T, et al. Electrophysiological correlates of bilateral and unilateral repetitive transcranial magnetic stimulation in patients with bipolar depression. Psychiatry research. 2016; 240: 364-75.
40- Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008; 33(2): 368-77.
41- Baumgartner T, Knoch D, Hotz P, Eisenegger C, Fehr E. Dorsolateral and ventromedial prefrontal cortex orchestrate normative choice. Nat Neurosci. 2011; 14(11): 1468-74.
42- Saraiva AC, Marshall L. Dorsolateral-ventromedial prefrontal cortex interactions during value-guided choice: a function of context or difficulty? J Neurosci. 2015; 35(13): 5087-8.
43- Downar J, Daskalakis ZJ. New targets for rTMS in depression: a review of convergent evidence. Brain Stimul. 2013; 6(3): 231-40.
44- Siegle GJ, Carter CS, Thase ME. Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. American Journal of Psychiatry. 2006; 163(4): 735-8.
45- Ariana-Kia E, Moradi A.R, Hatami M.The effectiveness of combined of brief behavioral activation therapy and mindfulness-based cognitive therapy in patients with major depressive disorder. Journal of Clinical Psychology. 2014; 6(21):15-27.
46- Bajbouj M, Padberg F. A perfect match: noninvasive brain stimulation and psychotherapy. European archives of psychiatry and clinical neuroscience. 2014; 264(1): 27-33.
47- Rahmanian M, Asbaghi E, Asbaghi M, Torabi-Makhsoos, S. Assessment of efficacy of cognitive behavior therapy and repetitive transcranial magnetic stimulation on depression symptoms reduction. Journal of Clinical Psychology. 2015; 7(26): 29-38.
48- Donse L, Padberg F, Sack AT, Rush AJ, Arns M. Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study. Brain stimulation. 2018; 11(2): 337-45.
49- Chen JJ, Liu Z, Zhu D, Li Q, Zhang H, Huang H, et al. Bilateral vs. unilateral repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomized controlled trials. Psychiatry Res. 2014; 219(1): 51-7.
50- Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014; 76(3): 176-85.
51- Kito S, Hasegawa T, Koga Y. Cerebral blood flow in the ventromedial prefrontal cortex correlates with treatment response to low-frequency right prefrontal repetitive transcranial magnetic stimulation in the treatment of depression. Psychiatry Clin Neurosci. 2012; 66(2): 138-45.
52- Dougherty DD, Weiss AP, Cosgrove GR, Alpert NM, Cassem EH, Nierenberg AA, et al. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. J Neurosurg. 2003; 99(6): 1010-7.
53- Beuzon G, Timour Q, Saoud M. Predictors of response to repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder. L'Encéphale. 2017; 43(1): 3-9.
54- Padberg F, Zwanzger P, Keck ME, Kathmann N, Mikhaiel P, Ella R, et al. Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology. 2002; 27(4): 638-45.
55- Pirmoradi M.R, Dolatshahi B, Rostami R, Mohammadkhani P, Dadkhah A. The effect of repetitive transcranial magnetic stimulation (rTMS) in clinical improvement and the signs reduction process of depression in patients with recurrent major depression disorder. Journal of Clinical Psychology. 2013; 4(16):51-64.
56- Rostami R, Kazemi R, Nitsche MA, Gholipour F, Salehinejad M. Clinical and demographic predictors of response to rTMS treatment in unipolar and bipolar depressive disorders. Clinical Neurophysiology. 2017; 128(10): 1961-70.